A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Status:
Suspended
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Thymic tumors are rare tumors, but represent the most common tumors of the anterior
mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to
spread to the pleura. In first line therapy, combination chemotherapy produces responses in
approximately 80% of patients. A number of single agents have activity in recurrent disease,
but none are curable. Patients with recurrent thymoma have limited treatment options, and
thus novel target modalities are needed.
At the Indiana University Simon Cancer Center (IUSCC), more patients with advance thymoma are
seen than any other institution in the country. Our main hypothesis is the PI3K pathway is an
important driver for growth and metastasis of thymoma and that inhibition of the PI3K pathway
is expected to produce clinically meaningful response in patients with recurrent thymoma.